Apalutamide interactions

Full monograph for Apalutamide Check it against another medicine

Medicines

514 documented

Severity

Mechanism

Medicines documented to interact with Apalutamide, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Abemaciclib	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abemaciclib and its pharmacologically active…	6 sources — open the full entry
Abiraterone Acetate	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abiraterone, which is partially metabolized by the…	8 sources — open the full entry
Acalabrutinib	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by…	7 sources — open the full entry
Alpelisib	Major	Metabolism	Coadministration of alpelisib with potent inducers of CYP450 3A4 may significantly reduce the plasma concentrations of alpelisib. The proposed mechanism, based…	8 sources — open the full entry
Amiodarone Hydrochloride	Major	Synergy	Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related…	45 sources — open the full entry
Amisulpride	Major	Synergy	Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the…	3 sources — open the full entry
Amlodipine Besilate	Major	Metabolism	Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…	35 sources — open the full entry
Amlodipine Besilate + Atenolol	Major	Metabolism	Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…	35 sources — open the full entry
Amlodipine Besilate + Atorvastatin	Major	Metabolism	Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…2 documented mechanisms	47 sources — open the full entry
Amlodipine Besilate + Benazepril Hydrochloride	Major	Metabolism	Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…	35 sources — open the full entry
Amlodipine Besilate + Olmesartan Medoxomil	Major	Absorption · Metabolism	Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…2 documented mechanisms	40 sources — open the full entry
Amlodipine Besilate + Telmisartan	Major	Metabolism	Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…	35 sources — open the full entry
Amlodipine Besilate + Valsartan	Major	Absorption · Metabolism	Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…2 documented mechanisms	40 sources — open the full entry
Apixaban	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of apixaban…	8 sources — open the full entry
Apremilast	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of apremilast, which is primarily metabolized by the…	5 sources — open the full entry
Arsenic Trioxide	Major	Synergy	Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the…	4 sources — open the full entry
Artemether + Lumefantrine	Major	Metabolism · Synergy	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are…3 documented mechanisms	14 sources — open the full entry
Axitinib	Major	Metabolism	Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily…	9 sources — open the full entry
Bisoprolol Fumarate + Amlodipine Besilate	Major	Metabolism	Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…	35 sources — open the full entry
Bortezomib	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of bortezomib, which is primarily…	10 sources — open the full entry
Brigatinib	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of brigatinib, which is partially metabolized by the…	9 sources — open the full entry
Brivaracetam	Major	Metabolism	Coadministration with potent inducers of CYP450 2C19 may decrease the plasma concentrations of brivaracetam. According to the prescribing information…	4 sources — open the full entry
Bupropion Hydrochloride	Major	Synergy	The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with selective serotonin…	19 sources — open the full entry
Cabozantinib	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme.	7 sources — open the full entry
Capmatinib Hydrochloride	Major	Metabolism	Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed…	5 sources — open the full entry
Ceritinib	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme.	3 sources — open the full entry
Citalopram Hydrobromide	Major	Synergy	Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	15 sources — open the full entry
Clozapine	Major	Synergy	Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation…	13 sources — open the full entry
Crizotinib	Major	Metabolism	Coadministration with strong CYP450 3A4 inducers may decrease plasma concentrations and pharmacologic effects of crizotinib, which is primarily metabolized by…	6 sources — open the full entry
Daclatasvir	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the…	6 sources — open the full entry
Daclatasvir + Sofosbuvir	Major	Absorption · Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the…2 documented mechanisms	17 sources — open the full entry
Darolutamide	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of…	6 sources — open the full entry
Dasatinib	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of dasatinib, which is primarily metabolized by the…	11 sources — open the full entry
Deflazacort	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of 21-desdeflazacort, the active…	6 sources — open the full entry
Dextromethorphan + Bupropion	Major	Synergy	The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with selective serotonin…	19 sources — open the full entry
Diltiazem Hydrochloride	Major	Metabolism	Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…	3 sources — open the full entry
Elacestrant	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elacestrant, which is primarily…	1 sources — open the full entry
Erdafitinib	Major	Metabolism	Coadministration with potent inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is…	2 sources — open the full entry
Escitalopram Oxalate	Major	Synergy	Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	13 sources — open the full entry
Everolimus	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the blood concentrations and pharmacologic effects…	6 sources — open the full entry
Fentanyl Citrate	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as…	12 sources — open the full entry
Finerenone	Major	Metabolism	Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily…	3 sources — open the full entry
Flibanserin	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by…	3 sources — open the full entry
Gatifloxacin	Major	Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…	28 sources — open the full entry
Gatifloxacin + Dexamethasone	Major	Metabolism · Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms	31 sources — open the full entry
Gilteritinib Fumarate	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of…	2 sources — open the full entry
Haloperidol	Major	Synergy	Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	14 sources — open the full entry
Ibrutinib	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.	4 sources — open the full entry
Iloperidone	Major	Synergy	Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	9 sources — open the full entry
Imatinib Mesylate	Major	Metabolism	Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of imatinib, which is primarily metabolized by the…	10 sources — open the full entry

Conditions

Conditions in which Apalutamide needs care, as documented in this source.

Cardiovascular Diseases
Moderate
Ischemic cardiovascular events, including events leading to death, occurred in patients receiving apalutamide. It is recommended to monitor for signs and symptoms of ischemic heart disease and to consider discontinuation of treatment for Grade 3 and 4 events. Care should be exercised when prescribing this agent in patients at risk of an ischemic cardiovascular event, such as in those patients with hypertension, diabetes, or dyslipidemia.
1 source
1. "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc. (2018):
Kidney Diseases
Moderate
No clinically significant differences in the pharmacokinetics of apalutamide or its major metabolite were observed in patients with mild to moderate renal impairment. The effect on patients with severe renal impairment or end-stage renal disease on apalutamide pharmacokinetics is unknown. Close monitoring of renal function is recommended in these patients.
1 source
1. "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc. (2018):
Liver Diseases
Moderate
No clinically significant differences in the pharmacokinetics of apalutamide or its major metabolite were observed in patients with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment. The effect on patients with severe hepatic impairment (Child-Pugh C) on apalutamide pharmacokinetics is unknown. Close monitoring of liver function is recommended in these patients.
1 source
1. "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc. (2018):
Osteoporosis
Moderate
Falls and fractures have occurred in patients receiving apalutamide. Care should be exercised when apalutamide is used in patients at risk for fractures or falls and in those patients with osteoporosis. It is recommended to evaluate patients for fracture and fall risk and to consider the use of bone-targeted agents as medically necessary.
1 source
1. "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc. (2018):
Seizures
Moderate
The use of apalutamide may cause seizures. It is recommended to discontinue this agent in patients who develop a seizure while on treatment. Care should be exercised when using apalutamide in patients at risk or with a history of seizure disorder.
1 source
1. "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc. (2018):

Therapeutic duplication

Drug classes that overlap with Apalutamide, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

antineoplastic hormones
The recommended maximum number of medicines in the 'antineoplastic hormones' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antineoplastic hormones' category.
Example product in the source data (US market): Letrozole/ribociclib

Medicines

Conditions

Cardiovascular Diseases

Kidney Diseases

Liver Diseases

Osteoporosis

Seizures

Therapeutic duplication

antineoplastic hormones